ReviewCommunications biology2026
The challenge of cell death switching in inflammasome-targeted therapies for bacterial and viral infections.
Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Inflammasome activation and pyroptosis are central to innate immune responses and play either protective or detrimental roles in host defense. Inhibiting these processes holds significant therapeutic promise for diseases exacerbated by inflammasome activation. However, clinically targeting this pathway remains challenging, as blocking pyroptosis may trigger alternative cell death pathways. In this mini-review, we summarize bacterial and viral infections in which inflammasome activation and pyroptosis are detrimental to host defense, explore the mechanisms underlying cell death switching, and discuss how effectively blocking multiple cell death pathways and potential interconversions represents a key consideration for current intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.